Immunic Appoints Seasoned Biopharma Executive Jon Congleton to Board, Chair of Compensation Committee

summarizeSummary

Immunic, Inc. appointed Jon Congleton, a highly experienced biopharmaceutical executive, to its Board of Directors and as Chair of the Compensation Committee, bringing critical expertise as the company progresses its lead MS program.

check_boxKey Events

• New Director Appointment

  Jon Congleton, a seasoned biopharmaceutical executive, was appointed to Immunic's Board of Directors, effective March 27, 2026. He will also serve as Chair of the Compensation Committee.

• Extensive Biopharmaceutical Experience

  Mr. Congleton brings nearly 40 years of experience, including CEO roles at Mineralys Therapeutics, Impel NeuroPharma, and Nivalis Therapeutics, and leadership positions at Teva Pharmaceutical Industries, with a strong background in CNS disorders and commercialization.

• Option Grant for Compensation

  In connection with his appointment, Mr. Congleton received an inaugural grant of options to purchase 500,000 shares of common stock, vesting monthly over three years, subject to shareholder approval of an increase to the equity incentive plan.

• Board Expansion

  The Board of Directors increased its size from eight to nine members to accommodate the new appointment.

auto_awesomeAnalysis

Immunic, Inc. has appointed Jon Congleton, a biopharmaceutical executive with nearly 40 years of experience, to its Board of Directors, effective March 27, 2026. This appointment, which was previously announced via press release on March 31, 2026, is significant as Mr. Congleton brings deep expertise in CNS disorders and commercialization, having served as CEO of other biotech firms and played a key role in the launch of Copaxone®. His experience is particularly relevant as Immunic advances its lead program, vidofludimus calcium, through pivotal clinical milestones for multiple sclerosis and aims to transition into a commercial-stage company. In connection with his appointment, Mr. Congleton received an inaugural grant of options to purchase 500,000 shares, which vest over three years and are subject to shareholder approval of an increase to the equity incentive plan. The board size has also increased from eight to nine directors.